Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 3/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28089569 | 0.75 | CHRM5 (0.42) | ALDH1A1KMT2AMEN1CYP2D6MAPT | |
| SCHEMBL28816160 | 0.74 | ALDH1A1 (0.39) | ALDH1A1NPSR1ALOX15KMT2AL3MBTL1 | |
| SCHEMBL3240535 | 0.74 | ALDH1A1 (0.37) | ALDH1A1NPSR1ALOX15KMT2AL3MBTL1 | |
| SCHEMBL5637950 | 0.74 | ALDH1A1 (0.37) | ALDH1A1NPSR1ALOX15KMT2AL3MBTL1 | |
| SCHEMBL28134027 | 0.74 | ALDH1A1 (0.42) | ALDH1A1NPSR1ALOX15KMT2AL3MBTL1 | |
| SCHEMBL2967401 | 0.73 | ACHE (0.42) | ALDH1A1KMT2AHTTTDP1MEN1 | |
| SCHEMBL104821 | 0.72 | ALDH1A1 (0.42) | ALDH1A1NPSR1ALOX15KMT2AL3MBTL1 | |
| SCHEMBL27887687 | 0.70 | ALDH1A1 (0.50) | ALDH1A1NPSR1ALOX15KMT2AL3MBTL1 | |
| SCHEMBL27871467 | 0.70 | ALDH1A1 (0.50) | ALDH1A1NPSR1ALOX15KMT2AL3MBTL1 | |
| SCHEMBL27659756 | 0.70 | ALDH1A1 (0.50) | ALDH1A1NPSR1ALOX15KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109721531-B | Novel liposome kinase inhibitor | 中国科学院合肥物质科学研究院 | 2022-07-29 | — | — | CN | claimed |
| WO-2020147097-A1 | NOVEL LIPOSOME KINASE INHIBITOR | 中国科学院合肥物质科学研究院 | 2020-07-23 | — | — | WO | claimed |
| CN-102549000-B | Fused thiazolo and oxazolopyrimidinones | TORRENT PHARMACEUTICALS LTD. (IN) | 2015-12-02 | — | — | CN | claimed |
| CN-103402996-B | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD) | NOVARTIS AG | 2015-02-11 | — | — | CN | claimed |
| EP-2004653-B1 | 3-SUBSTITUTED N-(ARYL- OR HETEROARYL)-PYRAZO[1,5-A]PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-12-30 | — | — | EP | claimed |
| CN-100471856-C | Bicyclic compounds and compostions as PDF inhibitors | IRM LLC (BM) | 2009-03-25 | — | — | CN | claimed |
| US-7217723-B2 | Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. | EISAI CO., LTD. (JP) | 2007-05-15 | — | — | US | claimed |
| CN-1860116-A | Bicyclic compounds and compostions as pdf inhibitors | IRM LLC (BM) | 2006-11-08 | — | — | CN | claimed |
| WO-2006025717-A1 | PYRROLO[2,3-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2006-03-09 | — | — | WO | claimed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | claimed |
| CN-109721531-B | Novel liposome kinase inhibitor | 中国科学院合肥物质科学研究院 | 2022-07-29 | — | — | CN | disclosed |
| WO-2020147097-A1 | NOVEL LIPOSOME KINASE INHIBITOR | 中国科学院合肥物质科学研究院 | 2020-07-23 | — | — | WO | disclosed |
| CN-104370811-B | A kind of novel crystal forms of quinoline compound and preparation method thereof | 广东东阳光药业有限公司 | 2019-02-12 | — | — | CN | disclosed |
| CN-107151232-A | The ternary cyclics of one class STAT3 protein inhibitors | 许军 | 2017-09-12 | — | — | CN | disclosed |
| CN-104540806-B | Azaheterocycles as BIR2 and/or BIR3 inhibitors | 霍夫曼-拉罗奇有限公司 | 2017-05-03 | — | — | CN | disclosed |
| EP-0540854-A2 | Preparation for promoting hair growth | Sansho Seiyaku Co., Ltd. (JP) | 1993-05-12 | — | — | EP | disclosed |
| EP-0536401-A1 | TRICYCLO COMPOUNDS, A PROCESS FOR THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-14 | — | — | EP | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| WO-1992000313-A1 | TRICYCLO COMPOUNDS, A PROCESS FOR THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-09 | — | — | WO | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | ALDH1A1 1391/4885NPSR1 455/4885ALOX15 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.